Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

View:
Post by MrMugsy on Sep 29, 2021 4:41pm

Novak ...

Raymond James analyst David Novak is firmly behind Knight Therapeutics, giving the company an “Outperform 2” rating in an update to clients on September 24.
...


Looking at the announced deal, Novak wrote in his report, “While not immediately accretive to Knight, the transaction is a return to form for Knight, doing what it does best: leveraging its infrastructure to in-license therapeutics for underserved jurisdictions, with significant forward-looking revenue potential, while putting minimal shareholder capital at risk.”
...


Novak projects continued modest growth for the company from a financial standpoint, forecasting revenue of $243 million in 2021 for a potential year-over-year increase of 21.5 per cent, followed by another jump to a projected $289 million for 2022, marking a potential year-over-year increase of 18.9 per cent.

https://www.cantechletter.com/2021/09/knight-therapeutics-strengthens-its-portfolio-raymond-james-says/
Comment by Chianchin on Sep 29, 2021 8:50pm
and share holders took advantage to sell on this guy report  who has being  wrong for eight Years 
Comment by MrMugsy on Sep 29, 2021 10:44pm
I don't think he's been wrong. I think the word you're looking for is "patient." 7 years in November - kindly work on the details ... they are important. : )
Comment by porksniffer on Sep 30, 2021 8:19pm
This turd is still churning on volume. Shareholders dumping with every bounce. Big holders want out. Mr. Bugs still thinks the 'old' JRG believers are still here. Big instutions are long gone, replaced by others who then also dump when they realize this is going nowhere. I got a good chuckle at #27 fastest growing company. Nearly 1 billion spent 'buying' growth in third world ...more  
Comment by MrMugsy on Sep 30, 2021 9:31pm
Unfortunately every word is "opinion without  a trace or reality" but it's fun to see you guess wrong. - those testing the waters and have been trying it over the past few years are the ones in/out.  They are providing the downward pressure but that's expected for a while - no evidence of big holders wanting out ... as big holders are the ones involved in annual AGM ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities